Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapyQi Xu, Jieer Ying, Xiaoqing Xu et al.|Oncogenesis|2023Cited by 24
The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinomaHui Zeng, Jingjing Li, Cong Luo et al.|Frontiers in Immunology|2023Cited by 17
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trialJingjing Li, Jieer Ying, Shurui Zhou et al.|Nature Communications|2025Cited by 12
Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II StudyQing Wei, Jieer Ying, Xiaoqing Xu et al.|The Oncologist|2024Cited by 10